MARKET

ONTXW

ONTXW

ONCONOVA THERAPE
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.0671
-0.0229
-25.44%
Closed 16:00 07/23 EDT
OPEN
0.0911
PREV CLOSE
0.0900
HIGH
0.1047
LOW
0.0600
VOLUME
415.93K
TURNOVER
--
52 WEEK HIGH
1.000
52 WEEK LOW
0.0201
MARKET CAP
--
P/E (TTM)
-0.0333
1D
5D
1M
3M
1Y
5Y
BRIEF-Onconova Therapeutics Regains Compliance With Nasdaq Continued Listing Requirement
reuters.com · 06/22 12:50
BRIEF-Onconova Therapeutics Announces The Initial Dosing Of The First Patient In The U.S. Phase 1 Clinical Trial Of On 123300
reuters.com · 05/21 12:05
BRIEF-Onconova Therapeutics Announces Reverse Stock Split And Decrease In Authorized Shares
reuters.com · 05/20 12:45
BRIEF-Onconova Therapeutics Inc - Received Letter From Nasdaq Indicating Co Failed To Comply With Minimum Bid Price Requirement Of Nasdaq Listing Rule
reuters.com · 05/14 12:09
BRIEF-Onconova Announces First Patient Dosed In Investigator-Initiated Phase 2 Study Of Rigosertib In Recessive Dystrophic Epidermolysis Bullosa-Associated Squamous Cell Carcinoma
reuters.com · 04/22 12:22
BRIEF-Onconova Therapeutics Announces Enrollment In Second Cohort Of Phase 1 Study With On 123300 In China
reuters.com · 04/01 13:03
BRIEF-Onconova Therapeutics Inc Announces Pricing Of $25 Million Public Offering Of Common Stock
reuters.com · 02/11 03:51
BRIEF-Onconova Therapeutics, Inc. Announces Proposed Public Offering Of Common Stock
reuters.com · 02/10 21:16
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ONTXW. Analyze the recent business situations of ONCONOVA THERAPE through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
EPS
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.89%
Pharmaceuticals & Medical Research
+0.92%
Key Executives
Chairman/Director
James Marino
President/Chief Executive Officer/Director
Steven Fruchtman
Chief Financial Officer
Mark Guerin
Vice President/General Counsel
Abraham Oler
Other
Mark Gelder
Director
Henry Bienen
Director
Jerome Groopman
Director
Viren Mehta
Director
Terri Shoemaker
Director
Jack Stover
Director
Anne Vanlent
No Data
About ONTXW
Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells. It has over three clinical-stage product candidates and various preclinical programs that target kinases, cellular metabolism or cell division in preclinical development. The Company's lead product candidate, rigosertib, is being tested in both intravenous (IV) and oral formulations as a single agent, and the oral formulation is also being tested in combination with azacitidine, in clinical trials for patients with myelodysplastic syndromes (MDS), and related cancers. Its other product candidates include Briciclib and Recilisib.

Webull offers kinds of Onconova Therapeutics Inc stock information, including NASDAQ:ONTXW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ONTXW stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ONTXW stock methods without spending real money on the virtual paper trading platform.